DR-328 Intratumoral microbiome characterisation to predict patient outcome in the context of immune-checkpoint inhibitors

Immune-checkpoint inhibitors are changing the treatment options for primary and metastatic tumor cancer patients. However, heterogeneity of response is observed as a consequence of e.g. tumor mutational burden and immune-surveillance. The aim of the current study is to provide a comprehensive comparison between metastatic and primary cancer tumors with respect to the intratumoral microbiome, with a specific focus on the association between the microbiome composition, intratumoral immune landscape, and immune checkpoint inhibitor response. The result of this study will contribute to a better understanding of the (potential) association between intratumoral microbes and tumor microenvironment immune status both primary and metastatic cancers, at the taxa level. Ultimately this work may contribute to the identification of biomarkers of immune checkpoint inhibitor response or new strategies to augment anti-tumour immunity.

Jeroen de Ridder, Universtair Medisch Centrum Utrecht (UMCU), the Netherlands